Syndax Pharmaceuticals, Inc. (SNDX) Stock Price & Analysis

Syndax Pharmaceuticals, Inc. (SNDX) closed at USD 13.57 on Thursday, October 22, 2026, up 3.19% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 13.15; the Oct 22, 2026 session ranged USD 13.06–13.58 on volume of 2,362,738 shares. Market capitalization is $1.21B, with a 52-week range of USD 12.8–25.59 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:50 UTC.

Also available as compact Markdown for AI agents: nexqual.com/SNDX.md

Key facts (SNDX)

• Last four reported quarters (through Jun 30, 2026): revenue $252M, net income -$221M (-87.5% margin) (SEC filings).
• 1 of 80 tracked superinvestors hold SNDX (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
• Insider open-market sales, last ~7 months: 4 Form 4 filings, $2.1M; 2 not under a Rule 10b5-1 plan ($152K); 1 by opportunistic insiders (1 outside 10b5-1 plans), 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 1.83 on a 1–5 scale) (12 analysts), mean target USD 37.27 (range 23–57).
• Total return with dividends: 1Y -7.6% vs S&P 500 +14.9%; 5Y -28.4% vs S&P 500 +80.3%.
• Next earnings: 2026-11-02, EPS estimate USD -0.49, revenue estimate $81.9M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (SNDX)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (SNDX)

P/S 4.8x · EV/Sales 5.0x · P/B 80.3x · Earnings yield -18.22% · Net debt $46.2M · EV $1.26B

Superinvestors (SEC 13F-HR, Q2 2026) (SNDX)

1 of 80 tracked investors hold SNDX. Each row is the investor's latest 13F; change is vs their prior-quarter share count.

Insider sales (SEC Form 4, open-market, last ~7 months) (SNDX)

2 of 4 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (SNDX)

Consensus Buy (mean 1.83 on a 1–5 scale), 12 analysts; mean target USD 37.27 (low 23, high 57).

Rating changes, last 120 days:

Total return (dividends reinvested) (SNDX)

SNDX revenue by product line (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

SNDX suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 26, 2026.

Companies that name SNDX in their SEC reports

SNDX company outlook (results filed Aug 4, 2026)

• “For the full year of 2026, the Company continues to expect total research and development plus selling, general and administrative expenses to be approximately $400 million, excluding the impact of $50 million in estimated non-cash stock compensation expense.”

Quoted word-for-word from the SEC 8-K results press release.

SNDX analyst estimates and revisions

SNDX options: expected move

Options price a move of about ±16.6% (±$2.25) by Nov 20, 2026, which includes earnings on Nov 2, 2026. Over the last 8 reports the stock moved ±10.8% on average.

30-day implied volatility 78.2% vs 61.4% realized over the last 30 trading days. Put/call ratio (volume) 0.37. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 23, 2026 at 09:50 UTC)

Technical Analysis (SNDX)

Nexqual's technical model rates SNDX "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 09:50 UTC.

Analyst Ratings (SNDX)

Wall Street analysts rate SNDX "Buy" based on 12 analysts, with a mean price target of USD 37.27 (range USD 23–57), per Nexqual as of October 23, 2026 at 09:50 UTC.

Earnings (SNDX)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 09:50 UTC.

Financials & Fundamentals (SNDX)

Source: Nexqual, October 23, 2026 at 09:50 UTC.

Financial Health Score (SNDX)

Nexqual rates Syndax Pharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of October 23, 2026 at 09:50 UTC.

Ownership (SNDX)

Source: Nexqual, October 23, 2026 at 09:50 UTC.

Leadership (SNDX)

Syndax Pharmaceuticals, Inc. is led by Michael A. Metzger, CEO & Director, per Nexqual as of October 23, 2026 at 09:50 UTC.

Major Backers & Investors (SNDX)

Notable institutional backers of Syndax Pharmaceuticals, Inc. include Kynam Capital Management, LP, Goldman Sachs, Bank of America Corporation, according to Nexqual as of October 23, 2026 at 09:50 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 23, 2026 at 09:50 UTC.

From Syndax Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• As of December 31, 2025, the in-licensed axatilimab composition-of-matter patent portfolio included two granted U.S. patents, 35 granted non-U.S. patents, including a granted Eurasian patent which has been validated in 3 countries and two granted EP patents which have been validated in 37 countries each, and 6 non-U.S. pending patent applications.
• We also co-own with Board of Regents, The University of Texas System six pending non-U.S. patent applications, one pending U.S. patent application, covering methods of treating cancer with combinations, including menin inhibitors and Bcl-2 inhibitors.
• In the United States, the FDA regulates drugs and biologics under the Federal Food, Drug, and Cosmetic Act the Public Health Service Act, and related regulations.
• We also rely on trade secrets, know-how, continuing technological innovation and in-licensing opportunities to develop and maintain our proprietary position.

Partnerships

• In March 2007, we entered into a license agreement with Bayer Schering Pharma AG, or Bayer, for a worldwide, exclusive license to develop and commercialize entinostat and any other products containing the same active ingredient.
• In March 2007, the Company entered into a license agreement with Bayer for a worldwide, exclusive license to develop and commercialize entinostat and any other products containing the same active ingredient.

Legal & Regulatory Risks (Item 1A, quoted)

• We are currently developing several product candidates. If we are unable to successfully complete clinical development of, obtain regulatory approval for, and commercialize our product candidates, our business prospects may be significantly harmed.
• Failure to comply with regulatory requirements or unanticipated problems with Revuforj or Niktimvo may result in various adverse actions such as the suspension or withdrawal of Revuforj or Niktimvo, closure of a facility or enforcement of substantial penalties or fines.
• Our products and product candidates may face future development and regulatory difficulties.
• Our products and product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial scope of their approved use, or result in significant negative consequences following any marketing approval.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:50 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt